BNTX vs. MRNA: BioNTech vs. Moderna Stock Comparison
How do BioNTech (BNTX) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BioNTech (BNTX) and Moderna (MRNA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Moderna (MRNA) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | BNTX | MRNA |
|---|---|---|
| Name | BioNTech SE American Depositary Share | Moderna Inc. |
| Country/Region | Germany | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 21.70 billion USD | 101.48 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | October 10, 2019 | December 7, 2018 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| Total Return (1Y) | -14.78% | 1,031.66% |
| Total Return (3Y, Annualized) | -3.99% | 58.68% |
| Total Return (5Y, Annualized) | -17.02% | 3.23% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| Volatility (1Y, Annualized) | 47.44% | 194.88% |
| Beta (5Y) | 1.30 | 1.08 |
| Max Drawdown (5Y) | -78.10% | -93.93% |
| Avg. Volume (3M) | 1.21M | 21.61M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| Sharpe Ratio (1Y) | -0.40 | 5.27 |
| Sortino Ratio (1Y) | -0.59 | 20.44 |
Profitability
ROE (TTM)
Both BioNTech (BNTX) at -8.14% and Moderna (MRNA) at -39.00% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-8.14%
- Max
- 109.18%
- Q3
- 6.23%
- BNTX
- -8.14%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.00%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- MRNA
- -39.00%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both BioNTech (BNTX) at -60.87% and Moderna (MRNA) at -141.43% report negative net margin values, usually indicating net losses over the period.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
-60.87%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BNTX
- -60.87%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-141.43%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- MRNA
- -141.43%
Operating Margin (TTM)
Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioNTech (BNTX) reports 30.28%, ranking against industry peers normally.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.28%
- Max
- 83.12%
- BNTX
- 30.28%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-557.93%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- MRNA
- -557.93%
Profitability Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| ROE (TTM) | -8.14% | -39.00% |
| ROA (TTM) | -4.04% | -13.26% |
| Net Margin (TTM) | -60.87% | -141.43% |
| Operating Margin (TTM) | 30.28% | -557.93% |
| Gross Margin (TTM) | 76.73% | -66.02% |
Growth
Revenue Growth
BioNTech (BNTX) at 4.32% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Neither BioNTech (BNTX) nor Moderna (MRNA) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| Revenue Growth (YoY) | 4.32% | -39.92% |
| Revenue Growth (3Y CAGR) | -45.06% | -53.30% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.55
- Max
- 25.13
- Q3
- 12.13
- BNTX
- 8.55
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.30
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRNA
- 2.30
- Min
- 0.10
Debt / Equity (MRQ)
BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Moderna (MRNA) at 0.19 runs a more typical debt-to-equity mix.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.02
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- BNTX
- 0.02
- Min
- 0.00
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- MRNA
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 8.55 | 2.30 |
| Debt / Equity (MRQ) | 0.02 | 0.19 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither BioNTech (BNTX) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BioNTech (BNTX) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BNTX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BioNTech (BNTX) nor Moderna (MRNA) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BNTX
- --
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- MRNA
- --
P/S Ratio (TTM)
BioNTech (BNTX) at 8.96 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.96
- Max
- 58.18
- Q3
- 25.77
- BNTX
- 8.96
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.55
- Max
- 58.18
- MRNA
- 45.55
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
BioNTech (BNTX) at 1.09 looks cheap against book in the lower P/B ratio quartile, while Moderna (MRNA) at 11.58 carries a premium in the upper quartile — a clear price-to-book gap.
BNTX
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.09
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BNTX
- 1.09
- Min
- -5.59
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.58
- Max
- 13.53
- MRNA
- 11.58
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BNTX | MRNA |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 8.96 | 45.55 |
| P/B Ratio (MRQ) | 1.09 | 11.58 |
| Free Cash Flow Yield (TTM) | -7.34% | 0.29% |